CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death

Hepatocellular carcinoma (HCC) patients usually fail to be treated because of drug resistance, including sorafenib. In this study, the effects of CASK in HCC were investigated using gain- or loss-of-function strategies by performing cell counting kit-8 assay, colony formation assay, flow cytometry,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Bisha, Bao, Chang, Jin, Luqi, Xu, Liang, Fan, Weimin, Lou, Weiyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260832/
https://www.ncbi.nlm.nih.gov/pubmed/34249726
http://dx.doi.org/10.3389/fonc.2021.681683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260832/
https://www.ncbi.nlm.nih.gov/pubmed/34249726
http://dx.doi.org/10.3389/fonc.2021.681683

Ejemplares similares